Samy T S, Raso V
Cancer Res. 1976 Dec;36(12):4378-81.
Antibodies directed toward the antitumor protein neocarzinostatin (NCS) have been produced in a rabbit by immunization with a highly purified NCS preparation. The antiserum was monospecific and reversed the antibacterial activity of NCS against Sarcina lutea. It cross-reacted with chemically modified derivatives of NCS and mitomalcin but failed to cross-react with macromomycin. A radioimmunoassay procedure has been developed utilizing the antiserum and a biologically active 125I-labeled derivative of NCS. The lower limit of detection by this radioimmunoassay, which involves a double antibody technique for the separation of antibody-bound and free antigen, was 1 X 10(-13) mole. The sensitivity of the assay is such that serum levels of NCS can be determined accurately after administration of the drug to rats at a single dose of 2 mg/kg. Since NCS is now undergoing clinical trial, the radioimmunoassay of the drug will be a valuable tool in clinical pharmacological studies.
通过用高度纯化的新制癌菌素（NCS）制剂免疫兔子，已产生了针对抗肿瘤蛋白新制癌菌素的抗体。抗血清具有单特异性，并且能逆转新制癌菌素对藤黄八叠球菌的抗菌活性。它能与新制癌菌素的化学修饰衍生物和丝裂霉素发生交叉反应，但不能与大霉素发生交叉反应。利用该抗血清和具有生物活性的125I标记的新制癌菌素衍生物开发了一种放射免疫测定方法。这种采用双抗体技术分离抗体结合抗原和游离抗原的放射免疫测定的检测下限为1×10^(-13)摩尔。该测定的灵敏度使得在以2毫克/千克的单剂量给大鼠给药后，能够准确测定血清中的新制癌菌素水平。由于新制癌菌素目前正在进行临床试验，该药物的放射免疫测定将成为临床药理学研究中的一种有价值的工具。
